Yahoo India Web Search

Sign In

Search results

      • OneSource (formerly Stelis Biopharma), promoted by Strides Pharma and its promoter Arun Kumar, got demerged from Strides Pharma, and renamed as OneSource last year.
      economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/onesource-in-talks-to-raise-rs-1670-crore-in-pre-listing-round/articleshow/113677721.cms

      OneSource in talks to raise Rs 1,670 crore in pre-listing round

  2. People also ask

  3. economictimes.indiatimes.com › industry › healthcareStrides secures shareholders' nod for OneSource specialty ...

    Sep 11, 2024 · Strides Pharma Science has received approval from shareholders and secured creditors to create OneSource, a specialty pharma CDMO. The company will now seek final approval from the NCLT, Mumbai Bench, and listing approvals from BSE and NSE. This move aims to unlock value for stakeholders upon OneSource's listing.

    • Viswanath Pilla

  4. www.careratings.com › upload › CompanyFilesOneSource Specialty Pharma Limited - Credit Rating

    The existence of experienced promoters with proven turnaround capabilities, ability to expand customer base and attract equity investments by leveraging established relationships, brand name of promoters, accredited manufacturing facilities and strong order book providing near term sales visibility.

  5. www.marketscreener.com › quote › stockOneSource Reportedly in Talks to Raise INR 16,700 Million in ...

    4 days ago · The promoters of OneSource Specialty Pharma Limited, a TPG Growth-backed specialty pharma contract development and manufacturing organisation , are in discussions with a clutch of investors including...

  6. www.moneycontrol.com › news › businessStrides Pharma to spin off CDMO, soft gelatin biz into ...

    Sep 25, 2023 · OneSource will be India’s first specialty pharma pure play CDMO, Strides Pharma said. Strides Pharma said on September 25 that it will spin off its CDMO (Contract Development & Manufacturing...

  7. Videos

    View all

  8. forum.valuepickr.com › t › strides-pharma-onesourceStrides Pharma/OneSource - The Last Stand Will Create Wealth?

    Apr 25, 2024 · OneSource will have three business segments - Soft Gel Business, SteriScience and Stelis. Each of these businesses are supposed to have margins in excess of 20% and some of them can even have margins exceeding 30%. For FY24, OneSource is supposed to have revenue of 145mn$ and EBITDA of around 36mn$ (i.e. 1200cr revenue and 300cr EBITDA roughly).

  9. www.careratings.com › upload › CompanyFilesSTRIDES PHARMA SCIENCE LIMITED July 12, 2024 - Credit Rating

    reduce. As of June 2024, the amount outstanding as against which Strides has extended CG to OneSource is ~Rs. 450 crores. Around 70% of the promoters’ shares are pledged, this is also expected to reduce over 90%. Existence of experienced promoters and established track record of promoters